The Effect of Hydromethanolic Extracts of Mangifera Indica Stem Bark and Leaf on Seizure Latency and Seizure Duration in Electroconvulsive Therapy-Induced Seizures in Male Wistar Rats
Main Article Content
Abstract
Electroconvulsive therapy (ECT) remains an effective intervention for severe psychiatric disorders but is associated with adverse seizure effectss. Natural products with neuroprotective properties, such as Mangifera indica, may offer safer adjunctive benefits. M. indica is rich in bioactive compounds with antioxidant, anti-inflammatory, and neuromodulatory properties. Their role in modulating seizure latency and duration in ECT-induced seizures remains underexplored. Male Wistar rats (n = 6/group) were assigned to: Control, ECT only, ECT + diazepam (5 mg/kg), ECT + stem bark extract (MSBE; 300 or 600 mg/kg), or ECT + leaf extract (MLE; 300 or 600 mg/kg). Extracts were administered orally for four weeks. Seizure latency and duration were recorded weekly following ECT induction. ECT-only rats showed reduced seizure latency (week 4: 1.90 ± 0.65 s) and prolonged duration (35.00 ± 0.74 s). Diazepam significantly increased latency (4.40 ± 1.29 s) and reduced duration (16.20 ± 0.70 s). Both MSBE and MLE significantly improved latency (5.60 ± 0.55 s to 6.30 ± 0.57 s) and reduced duration (16.60 ± 0.48 s to 19.60 ± 0.37 s; p < 0.05 vs. ECT only), with MSBE 600 mg/kg producing the most pronounced effects. M. indica extracts demonstrated significant anticonvulsant activity in ECT-induced seizures, with efficacy comparable to diazepam. The effects may be linked to modulation of neuronal excitability and oxidative stress pathways. These findings suggest that M. indica stem bark and leaf extracts possess significant anticonvulsant potential in ECT-induced seizures, likely mediated by modulation of neuronal excitability.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Ahmed, A., Ibrahim, M., & Yusuf, M. (2023). Neurobehavioral effects of electroconvulsive therapy in rats: Mechanisms and mitigation strategies. Journal of Neuroscience Research, 101(2), 145-154.
II. Akinmoladun, F. J., Lawal, O. A., & Olaleye, T. M. (2022). Antioxidant and neuroprotective activities of Mangifera indica: a review of pharmacological evidence. Journal of Ethnopharmacology, 292, 115229.
III. Akinmoladun, F. O., Komolafe, T. O., & Farombi, E. O. (2022). Neuroprotective mechanisms of polyphenolic compounds in neurodegenerative diseases: Targeting oxidative stress and neuroinflammation. Biomedicine & Pharmacotherapy, 153, 113311.
IV. Ali, R. A., Yimer, E. M., & Zewdu, W. D. (2022). Oxidative stress and its implication in epilepsy and seizure disorders. Oxidative Medicine and Cellular Longevity, 2022, Article ID 6515360.
V. Almeida, A. M., da Silva, A. P., & Martins, G. N. (2022). Plant polyphenols as neuroprotective agents in epilepsy and seizure disorders. Frontiers in Pharmacology, 13, 943658.
VI. Arias, B. et al. (2020). Dopaminergic and cholinergic interplay in seizure susceptibility. Epilepsy Res, 159, 106257.
VII. Bamigboye, M. O., Omotoso, O. T., & Ajibade, A. J. (2024). Modulatory effect of mango leaf extract on neurotransmitter levels in seizure-induced rats. Metabolic Brain Disease, 39(1), 55–63.
VIII. Chauhan, A., Sharma, P., & Sandhir, R. (2020). Protective effect of mangiferin in kainic acid-induced seizures and neurotoxicity in rats. Neurochemical Research, 45(4), 823–834. https://doi.org/10.1007/s11064-020-02978-0
IX. Chen, Q. et al. (2023). Targeting GABAergic dysfunction in seizure disorders. Front Neurol, 14, 1167012.
X. Chittka, T., Schmitz, C., & Bartsch, T. (2022). Cognitive side effects of electroconvulsive therapy: Clinical relevance and neurobiological mechanisms. Frontiers in Neuroscience, 16, 897435. https://doi.org/10.3389/fnins.2022.897435
XI. Dhir, A., & Naidu, P. S. (2007). Seizure suppression and cognition improvement following combined administration of acetylcholinesterase inhibitor and GABAergic agents in mice. Seizure, 16(4), 340–347. https://doi.org/10.1016/j.
XII. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2023). Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine, 29(2), 322–330. https://doi.org/10.1038/s41591-022-02154-9
XIII. Fountoulakis, K. N., Papadopoulou, M., & Moutou, K. (2021). Benzodiazepines in electroconvulsive therapy: A review of neurobiological interactions. Clinical Psychopharmacology and Neuroscience, 19(1), 14–24. https://doi.org/10.9758/cpn.2021.19.1.14
XIV. Inozemtsev, A. N., Khaustova, O. A., & Emelin, A. Y. (2021). Repeated electroconvulsive shocks induce hippocampal oxidative stress and cognitive dysfunction in rats. Neuroscience Letters, 763, 136188. https://doi.org/10.1016/j.neulet.2021.136188
XV. Jaiswal, A., Kumar, D., & Singh, R. (2023). Neurotherapeutic potential of Mangifera indica and its bioactive compound mangiferin: Mechanistic insights and preclinical evidence. Journal of Ethnopharmacology, 310, 116420. https://doi.org/10.1016/j.jep.2022.116420
XVI. Kabir, M. T., Rahman, M. S., Behl, T., et al. (2023). Therapeutic promise of mangiferin against neurodegenerative disorders: Molecular mechanisms and potential clinical implications. Biomedicine & Pharmacotherapy, 160, 114313. https://doi.org/10.1016/j.biopha.2023.114313
XVII. Khalid, S., Ahmad, A., & Ahmed, S. (2021). Systemic complications of electroconvulsive therapy: A comprehensive review. Psychiatric Clinics of North America, 44(1), 153–170.
XVIII. Kumar, A., Patnaik, R., & Deshmukh, R. (2020). Glutamatergic dysfunction in epilepsy: Potential of targeting NMDA receptors for therapeutic intervention. Current Neuropharmacology, 18(10), 901–913. https://doi.org/10.2174/1570159X18666200403124636
XIX. Obembe, A., Idowu, A. O., Adebayo, A., & Omotoso, G. O. (2022). Electroconvulsive therapy: Mechanisms of action and biological targets. Neuroscience and Biobehavioral Reviews, 139, 104731. https://doi.org/10.1016/j.neubiorev.2022.104731
XX. Ogundele, M. O., Udo, A. A., & Okonkwo, C. J. (2024). Natural polyphenols in seizure models: Evidence for motor and cognitive improvement. Brain Research Bulletin, 204, 98–106. https://doi.org/10.1016/j.brainresbull.2024.02.005
XXI. Ojo, O. A., Anthony, A. A., & Adelakun, A. A. (2023). Neuroprotective and anti-seizure properties of natural antioxidants: Evidence from animal models. Antioxidants, 12(3), 579. https://doi.org/10.3390/antiox12030579
XXII. Olaleye, T. M., Bello, O. R., & Oyelowo, O. T. (2021). Cognitive-enhancing effect of Mangifera indica in experimental models of neurotoxicity. Journal of Basic and Clinical Physiology and Pharmacology, 32(4), 387–394. https://doi.org/10.1515/jbcpp-2020-0510
XXIII. Olawale, O. O., Adeyemi, T. A., & Olatunji, L. A. (2023). GC–MS analysis and bioactive potential of hydromethanolic stem bark extract of Mangifera indica. Journal of Ethnopharmacology, 309, 116327. https://doi.org/10.1016/j.jep.2023.116327
XXIV. Pardo-Andreu, G. L., Barroso, M. P., & Delgado, R. (2020). Antioxidant and neuroprotective properties of mangiferin: A review of preclinical evidence. Molecules, 25(18), 4097. https://doi.org/10.3390/molecules25184097
XXV. Rocchi, L., Di Gregorio, F., & Rossi, S. (2023). Repeated electroconvulsive therapy increases neural excitability and oxidative stress in preclinical models. Brain Research Bulletin, 194, 165–174. https://doi.org/10.1016/j.brainresbull.2023.01.002
XXVI. Rogawski, M. A., Löscher, W., & Rho, J. M. (2020). Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harbor Perspectives in Medicine, 10(10), a034025. https://doi.org/10.1101/cshperspect.a034025
XXVII. Shah, S. A., Malik, S., & Ullah, R. (2023). Plant-derived neuroprotective agents modulating BDNF and synaptic plasticity. Journal of Ethnopharmacology, 309, 116327. https://doi.org/10.1016/j.jep.2023.116327
XXVIII. Sharma, S., Taliyan, R., & Sharma, P. L. (2019). Neuroprotective effects of pioglitazone in electroconvulsive shock-induced cognitive impairment in rats. Brain Research Bulletin, 153, 1–10. https://doi.org/10.1016/j.brainresbull.2019.08.006
XXIX. Silva, L. M., Costa, M. C., & Lima, T. T. (2021). Mangiferin protects against glutamate-induced neurotoxicity: Role of GABAergic transmission. Molecular Neurobiology, 58(1), 225–236. https://doi.org/10.1007/s12035-020-02171-7
XXX. Soman, S., Rajamanickam, C., Rauf, A., et al. (2021). Therapeutic potential of mangiferin against neurodegenerative diseases. Environmental Toxicology and Pharmacology, 81, 103532. https://doi.org/10.1016/j.etap.2020.103532
XXXI. Treiman, D. M. (2001). GABAergic mechanisms in epilepsy. Epilepsia, 42(Suppl 3), 8–12. https://doi.org/10.1046/j.1528-1157.2001.042suppl.3008.x
XXXII. Yuen, A. W. C., Al-Sadawi, M., & Chan, E. W. (2022). Seizure threshold and seizure susceptibility in animal models: Impact on translational validity. Epilepsy Research, 183, 106937. https://doi.org/10.1016/j.eplepsyres.2022.106937
XXXIII. Zhang, Y., Wang, Y., & Liu, T. (2023). Mitochondrial dysfunction in epilepsy and related neuroprotection. Free Radical Biology and Medicine, 200, 208–218.